S&P 500   5,124.73 (-1.43%)
DOW   37,970.72 (-1.27%)
QQQ   437.49 (-1.77%)
AAPL   175.74 (+0.40%)
MSFT   420.46 (-1.75%)
META   511.88 (-2.16%)
GOOGL   157.41 (-1.25%)
AMZN   185.48 (-1.89%)
TSLA   170.71 (-2.23%)
NVDA   885.24 (-2.31%)
AMD   162.86 (-4.48%)
NIO   4.11 (-7.85%)
BABA   71.84 (-4.02%)
T   16.28 (-0.85%)
F   12.53 (-3.91%)
MU   122.64 (-3.82%)
GE   154.11 (-2.09%)
CGC   7.88 (-3.31%)
DIS   114.00 (-2.69%)
AMC   2.67 (-4.64%)
PFE   25.93 (-1.56%)
PYPL   64.18 (-2.46%)
XOM   120.79 (-0.82%)
S&P 500   5,124.73 (-1.43%)
DOW   37,970.72 (-1.27%)
QQQ   437.49 (-1.77%)
AAPL   175.74 (+0.40%)
MSFT   420.46 (-1.75%)
META   511.88 (-2.16%)
GOOGL   157.41 (-1.25%)
AMZN   185.48 (-1.89%)
TSLA   170.71 (-2.23%)
NVDA   885.24 (-2.31%)
AMD   162.86 (-4.48%)
NIO   4.11 (-7.85%)
BABA   71.84 (-4.02%)
T   16.28 (-0.85%)
F   12.53 (-3.91%)
MU   122.64 (-3.82%)
GE   154.11 (-2.09%)
CGC   7.88 (-3.31%)
DIS   114.00 (-2.69%)
AMC   2.67 (-4.64%)
PFE   25.93 (-1.56%)
PYPL   64.18 (-2.46%)
XOM   120.79 (-0.82%)
S&P 500   5,124.73 (-1.43%)
DOW   37,970.72 (-1.27%)
QQQ   437.49 (-1.77%)
AAPL   175.74 (+0.40%)
MSFT   420.46 (-1.75%)
META   511.88 (-2.16%)
GOOGL   157.41 (-1.25%)
AMZN   185.48 (-1.89%)
TSLA   170.71 (-2.23%)
NVDA   885.24 (-2.31%)
AMD   162.86 (-4.48%)
NIO   4.11 (-7.85%)
BABA   71.84 (-4.02%)
T   16.28 (-0.85%)
F   12.53 (-3.91%)
MU   122.64 (-3.82%)
GE   154.11 (-2.09%)
CGC   7.88 (-3.31%)
DIS   114.00 (-2.69%)
AMC   2.67 (-4.64%)
PFE   25.93 (-1.56%)
PYPL   64.18 (-2.46%)
XOM   120.79 (-0.82%)
S&P 500   5,124.73 (-1.43%)
DOW   37,970.72 (-1.27%)
QQQ   437.49 (-1.77%)
AAPL   175.74 (+0.40%)
MSFT   420.46 (-1.75%)
META   511.88 (-2.16%)
GOOGL   157.41 (-1.25%)
AMZN   185.48 (-1.89%)
TSLA   170.71 (-2.23%)
NVDA   885.24 (-2.31%)
AMD   162.86 (-4.48%)
NIO   4.11 (-7.85%)
BABA   71.84 (-4.02%)
T   16.28 (-0.85%)
F   12.53 (-3.91%)
MU   122.64 (-3.82%)
GE   154.11 (-2.09%)
CGC   7.88 (-3.31%)
DIS   114.00 (-2.69%)
AMC   2.67 (-4.64%)
PFE   25.93 (-1.56%)
PYPL   64.18 (-2.46%)
XOM   120.79 (-0.82%)

Sangamo Therapeutics (SGMO) Earnings Date, Estimates & Call Transcripts

$0.55
+0.00 (+0.46%)
(As of 01:38 PM ET)

Earnings Summary

Upcoming
Earnings Date
May. 13Estimated
Actual EPS
(Mar. 13)
-$0.34 Missed By -$0.09
Consensus EPS
(Mar. 13)
-$0.25
Skip Charts & View Estimated and Actual Earnings Data

SGMO Earnings Estimates and Actuals by Quarter

The chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.

SGMO Estimated and Actual Revenue by Quarter

The chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter.

Sangamo Therapeutics Analyst EPS Estimates

QuarterNumber of EstimatesLow EstimateHigh EstimateAverage EstimateCompany Guidance
Q1 20242($0.26)($0.10)($0.18) 
Q2 20242($0.13)($0.10)($0.12) 
Q3 20242($0.14)($0.13)($0.14) 
Q4 20241$0.07$0.07$0.07 
FY 20247($0.46)($0.26) ($0.36)

SGMO Earnings Date and Information

Sangamo Therapeutics last announced its quarterly earnings data on March 13th, 2024. The biopharmaceutical company reported ($0.34) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.25) by $0.09. The company earned $2.04 million during the quarter, compared to the consensus estimate of $8.96 million. Sangamo Therapeutics has generated ($1.47) earnings per share over the last year (($1.47) diluted earnings per share). Earnings for Sangamo Therapeutics are expected to grow in the coming year, from ($0.54) to ($0.27) per share. Sangamo Therapeutics has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Monday, May 13th, 2024 based off prior year's report dates.

Sangamo Therapeutics Earnings History by Quarter

DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueCall Transcript
5/13/2024
Estimated)
------- 
3/13/2024Q4 2023($0.25)($0.34)($0.09)($0.34)$8.96 million$2.04 million
11/1/2023Q3 2023($0.33)($0.34)($0.01)($0.09)$10.17 million$9.40 million
8/8/2023Q2 2023($0.35)($0.37)($0.02)($0.08)$22.33 million$6.84 million
5/8/2023Q1 2023$0.14$0.12($0.02)$0.12$158.00 million$157.96 million
2/22/2023Q4 2022($0.36)($0.32)+$0.04($0.32)$26.86 million$27.23 million    
11/3/2022Q3 2022($0.35)($0.34)+$0.01($0.34)$27.01 million$26.46 million
8/4/2022Q2 2022($0.35)($0.29)+$0.06($0.29)$24.63 million$29.38 million    
5/5/2022Q1 2022($0.32)($0.30)+$0.02($0.30)$27.29 million$28.20 million    
2/24/2022Q4 2021($0.34)($0.26)+$0.08($0.26)$27.36 million$27.99 million    
11/4/2021Q3 2021($0.34)($0.33)+$0.01($0.33)$25.96 million$28.60 million    
8/5/2021Q2 2021($0.30)($0.33)($0.03)($0.33)$29.72 million$27.87 million    
5/4/2021Q1 2021($0.29)($0.32)($0.03)($0.32)$24.20 million$26.30 million  

Sangamo Therapeutics Earnings - Frequently Asked Questions

When is Sangamo Therapeutics's earnings date?

Sangamo Therapeutics has not confirmed its next earnings publication date, but the company's estimated earnings date is Monday, May 13th, 2024 based off last year's report dates. Learn more on SGMO's earnings history.

Did Sangamo Therapeutics beat their earnings estimates last quarter?

In the previous quarter, Sangamo Therapeutics (NASDAQ:SGMO) missed the analysts' consensus estimate of ($0.25) by $0.09 with a reported earnings per share (EPS) of ($0.34). Learn more on analysts' earnings estimate vs. SGMO's actual earnings.

How much revenue does Sangamo Therapeutics generate each year?

Sangamo Therapeutics (NASDAQ:SGMO) has a recorded annual revenue of $176.23 million.

How much profit does Sangamo Therapeutics generate each year?

Sangamo Therapeutics (NASDAQ:SGMO) has a recorded net income of -$257.83 million. SGMO has generated -$1.47 earnings per share over the last four quarters.

What is Sangamo Therapeutics's EPS forecast for next year?

Sangamo Therapeutics's earnings are expected to grow from ($0.54) per share to ($0.27) per share in the next year.


More Earnings Resources from MarketBeat

This page (NASDAQ:SGMO) was last updated on 4/12/2024 by MarketBeat.com Staff

From Our Partners